Exploring microarray patches for HIV prevention in SA

Genesis Analytics partnered with PATH to explore the acceptability, programmatic fit and usability of microarray patches (MAPs) as an alternative delivery mechanism for HIV pre-exposure prophylaxis (PrEP) and multipurpose prevention technologies (MPTs) in South Africa.

MAPs are innovative, discreet, self-administered drug delivery technologies that have the potential to improve adherence to HIV PrEP and expand access to long-acting contraceptives. To assess the hypothetical acceptability of MAPs, Genesis conducted focus group discussions and key informant interviews with potential end users and key stakeholders across three South African provinces.

The study gathered insights into users’ attitudes and preferences, as well as stakeholders’ perspectives on features and characteristics that could make MAPs more acceptable and usable. It also examined the feasibility of integrating this novel technology into South Africa’s health system, especially in resource-constrained settings.

The findings equip the PATH team and its partners with critical evidence to guide the development of MAPs for HIV PrEP and as MPTs, ensuring that these technologies align with the needs and concerns of end users. Results from this study were published in an article available here.